Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts

ABSTRACT: The VEGF targeted antiangiogenic drug bevacizumab has shown varying results in clinical trials of breast cancer. Identifying robust biomarkers for selecting patients that may benefit from bevacizumab treatment and for monitoring of response is important for the future use of this drug. Two established xenograft models representing basal-like and luminal-like breast cancer were used to study bevacizumab treatment response on the metabolic and gene expression levels. Mice given no treatment or treated with bevacizumab, doxorubicin or the combination of these two drugs were sacrificed at day 3 or 10. High resolution magic angle spinning magnetic resonance spectroscopy (HR MAS MRS) and gene expression microarray analysis was performed on all tumor samples. Combination treatment with bevacizuma

ORGANISM(S): Homo sapiens

SUBMITTER: Borgan Eldrid 

PROVIDER: S-ECPF-GEOD-37543 | biostudies-other |

REPOSITORIES: biostudies-other